DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 1 What's - 1 Lilly - 1 Lilly's - 1 Carter Gould - 1 Gould - 1 orforglipron - 1 Bank of America's Geoff Meacham - 1
Top related locs:
Novo
Top related orgs:
American Diabetes Association - 1 Wall - 1 Novo Nordisk - 1 Barclays - 1 Bank of America's - 1 JPMorgan - 1 Lilly - 1 BMO Capital - 1

Search resuls for: "Carter Gould"


3 mentions found


☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
  + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.
Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
☆ Sell biopharma stock Amgen ahead of its obesity drug update, Barclays says
  + stars: | 2022-10-31 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Investors should sell biopharma stock Amgen ahead of its obesity drug update next week, according to Barclays. Analyst Carter Gould downgraded Amgen to underweight from equal weight, saying there are high expectations around its obesity drug AMG133 after the stock's rally this month. Amgen shares outperformed nearly all its peers this month, even companies that have reported strong third-quarter results, after announcing at the start of October that it will disclose more obesity drug data, according to Barclays. In short, we think AMGN shares could come under pressure after the recent gains on the back of this update," the analyst wrote. The analyst's $234 price target represents 14.5% downside from where Amgen shares closed Friday at $273.81.
0 next >>
Total: 3